Compass Therapeutics (CMPX) News Today → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free CMPX Stock Alerts $1.48 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCompass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treatedfinance.yahoo.com - April 25 at 1:06 PMCompass Therapeutics Stock (NASDAQ:CMPX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 17 at 4:08 PMCompass Therapeutics' (CMPX) Buy Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - April 17 at 3:56 AMCompass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwrightmarketbeat.com - April 16 at 1:28 PMCompass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Decline in Short Interestmarketbeat.com - April 14 at 7:21 PMCompass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conferenceglobenewswire.com - April 12 at 8:00 AMCompass Therapeutics reports potential in tumor treatmentinvesting.com - April 11 at 9:39 AMCompass Therapeutics to Participate in the Stifel Targeted Oncology Daysfinance.yahoo.com - April 10 at 8:09 AMCompass Therapeutics to Participate in the Stifel Targeted Oncology Daysglobenewswire.com - April 10 at 8:00 AMCompass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - April 9 at 12:00 PMCompass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic Milestonesmarkets.businessinsider.com - March 25 at 2:46 AM3 Penny Stocks With the Power to 10X Your $1K Investmentinvestorplace.com - March 24 at 4:00 PMCompass Therapeutics' (CMPX) "Outperform" Rating Reaffirmed at Wedbushmarketbeat.com - March 22 at 10:25 AMCompass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy Ratingmarkets.businessinsider.com - March 22 at 12:12 AMCompass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at HC Wainwrightmarketbeat.com - March 21 at 11:27 AMCompass Therapeutics Reports 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 21 at 9:00 AMShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Declines By 6.6%marketbeat.com - March 18 at 2:23 PMWith 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersfinance.yahoo.com - March 12 at 7:37 AMFmr LLC Decreases Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)marketbeat.com - March 8 at 4:25 AMCompass Therapeutics to Participate in the Leerink Partners Global Biopharma Conferenceglobenewswire.com - February 29 at 8:00 AMCompass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trialfinance.yahoo.com - February 28 at 12:43 PMCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Monashee Investment Management LLCmarketbeat.com - February 25 at 10:47 AMCompass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Knowmsn.com - February 8 at 2:06 PMLeerink Partnrs Comments on Compass Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CMPX)marketbeat.com - February 8 at 7:30 AMCompass Therapeutics Inc Ordinary Sharesmorningstar.com - February 2 at 6:45 PMWe're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Ratefinance.yahoo.com - January 31 at 8:43 AMShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 8.1%marketbeat.com - January 15 at 2:51 PMCompass Therapeutics Provides Corporate Updatefinance.yahoo.com - January 5 at 8:20 AMCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Updatemarketbeat.com - December 31 at 5:18 PMCompass Therapeutics Insider Ups Holding During Yearfinance.yahoo.com - December 20 at 9:44 AMCompass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 17 at 10:23 AMCompass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developmentsfinance.yahoo.com - November 17 at 10:23 AMCompass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornermsn.com - November 14 at 12:36 PMTD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)markets.businessinsider.com - November 3 at 7:49 AMInstrument Name Compass Therapeutics Inc Instrument Symbol (CMPX-Q)theglobeandmail.com - September 27 at 9:01 PMHere's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situationfinance.yahoo.com - August 24 at 9:05 AMHC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy Recommendationmsn.com - August 3 at 10:23 PMCompass Therapeutics GAAP EPS of -$0.09msn.com - August 3 at 12:21 PMCompass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 3 at 12:21 PMCompass Therapeutics added to Russell indexesmsn.com - June 22 at 6:52 PMCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexesfinance.yahoo.com - June 22 at 6:52 PMCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexesfinance.yahoo.com - June 22 at 6:52 PMCitigroup Inc. Boosts Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)marketbeat.com - June 4 at 4:49 AMCompass Therapeutics to Participate in Upcoming Investor Eventsfinance.yahoo.com - June 1 at 2:33 PMCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Buy" from Brokeragesmarketbeat.com - May 31 at 3:34 AMSVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)markets.businessinsider.com - May 10 at 12:32 AMCompass Therapeutics, Inc. (NASDAQ:CMPX) Forecasted to Post FY2027 Earnings of $1.94 Per Sharemarketbeat.com - May 8 at 4:50 AMCompass Therapeutics: Q1 Earnings Insightsmsn.com - May 4 at 1:48 PMCompass Therapeutics Reports First Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - May 4 at 8:48 AMCompass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQfinance.yahoo.com - April 26 at 9:37 AM Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Medicare Supplement Insurance? (Ad)Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here CMPX Media Mentions By Week CMPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.000.41▲Average Medical News Sentiment CMPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼10▲CMPX Articles Average Week Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PSTX News ELEV News XFOR News IPSC News OPT News PCB News IPHA News ADVM News ABOS News CRDF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
